Los Angeles Capital Management LLC Cuts Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Los Angeles Capital Management LLC trimmed its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 19.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 17,545 shares of the medical instruments supplier’s stock after selling 4,290 shares during the period. Los Angeles Capital Management LLC’s holdings in LeMaitre Vascular were worth $996,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. DekaBank Deutsche Girozentrale purchased a new stake in shares of LeMaitre Vascular during the 3rd quarter valued at $38,000. Campbell & CO Investment Adviser LLC raised its position in LeMaitre Vascular by 78.8% in the third quarter. Campbell & CO Investment Adviser LLC now owns 5,329 shares of the medical instruments supplier’s stock worth $290,000 after acquiring an additional 2,349 shares during the period. Panagora Asset Management Inc. bought a new stake in LeMaitre Vascular in the third quarter worth about $315,000. Quantbot Technologies LP boosted its stake in LeMaitre Vascular by 709.6% in the third quarter. Quantbot Technologies LP now owns 7,578 shares of the medical instruments supplier’s stock valued at $413,000 after acquiring an additional 6,642 shares during the last quarter. Finally, Riverwater Partners LLC grew its position in shares of LeMaitre Vascular by 2.5% during the 4th quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock valued at $466,000 after acquiring an additional 198 shares during the period. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $76.00 on Friday. The company has a market capitalization of $1.71 billion, a P/E ratio of 50.33, a P/E/G ratio of 2.99 and a beta of 0.88. LeMaitre Vascular, Inc. has a 52-week low of $44.27 and a 52-week high of $76.24. The company has a fifty day moving average of $66.67 and a 200-day moving average of $59.46.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.05. The firm had revenue of $53.48 million during the quarter, compared to analysts’ expectations of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.27 EPS. As a group, analysts forecast that LeMaitre Vascular, Inc. will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th will be paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.84%. The ex-dividend date of this dividend is Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Insider Transactions at LeMaitre Vascular

In related news, Director David B. Roberts sold 5,025 shares of the stock in a transaction on Monday, May 6th. The shares were sold at an average price of $75.62, for a total transaction of $379,990.50. Following the transaction, the director now owns 14,114 shares of the company’s stock, valued at approximately $1,067,300.68. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other LeMaitre Vascular news, Director David B. Roberts sold 5,025 shares of the company’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $75.62, for a total transaction of $379,990.50. Following the completion of the sale, the director now directly owns 14,114 shares in the company, valued at $1,067,300.68. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO George W. Lemaitre sold 68,906 shares of LeMaitre Vascular stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $75.70, for a total value of $5,216,184.20. Following the completion of the transaction, the chief executive officer now owns 2,133,428 shares in the company, valued at approximately $161,500,499.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 195,967 shares of company stock worth $14,072,324. 10.79% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

LMAT has been the topic of several research analyst reports. Barrington Research upped their price objective on LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Stifel Nicolaus raised LeMaitre Vascular from a “hold” rating to a “buy” rating and upped their price target for the company from $59.00 to $75.00 in a research report on Friday, April 26th. StockNews.com raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. JMP Securities upped their price objective on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a report on Friday, May 3rd. Finally, KeyCorp assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday, February 6th. They issued a “sector weight” rating for the company. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $73.83.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.